Ozmosi | Dienogest Drug Profile

Product Description

Dienogest is an oral progestin that has been investigated extensively in the treatment of endometriosis. Danazol is an androgenic steroid that is effective in treating the signs and symptoms of endometriosis, but its use is limited by adverse effects on lipid metabolism and by weight gain, edema, acne, vaginal dryness, hot flushes, oily skin, hirsutism, liver toxicity, and breast atrophy (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3140813/)

Mechanisms of Action: PR Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Approved

Approved Indications: None

Known Adverse Events: None

Company: Bayer
Company Location:
Company CEO: Werner Baumann
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Dienogest

Countries in Clinic: United States

Active Clinical Trial Count: 2

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Contraception|Hirsutism

Trial ID	Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success	Latest Trial Update Date	Data Updated
2021-002178-17	2021-002178-17	P3	Completed	Hirsutism	2023-12-05		2025-05-06	Primary Completion Date\|Study Completion Date\|Treatments\|Trial Status
NCT03945513	LPRI424/303	P3	Completed	Contraception	2023-06-30	17%	2023-11-15	Primary Endpoints\|Study Completion Date\|Treatments\|Trial Status

Recent News Events

Date	Type	Title
06/07/2024	News Article	Female Contraceptive Market size is set to grow by USD 4.57 billion from 2024-2028, Increasing adoption of innovative marketing strategies to boost the market growth, Technavio
09/18/2023	News Article	PC VR Headsets market study targets key players, stakeholders, and other participants who will be able to stay current on current and upcoming business developments using 8.6% CAGR
05/17/2022	News Article	Exo Therapeutics Appoints Stephanos Ioannidis as Executive Vice President, Drug Discovery and Catherine Scholz as Senior Vice President, Program Management
01/21/2019	News Article	Global Endometriosis Industry

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

Session Expiring Soon

Dienogest

Alternative Names: dienogest, visanne, natazia, bay86-5258 Clinical Status: Inactive Latest Update: 2025-10-02 Latest Update Note: Clinical Trial Update